Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog

Xenobiotica

Volumn 32, Issue 10, 2002, Pages 907-924

  Slatter, J G ^a   Adams, L A ^a   Bush, E C ^a   Chiba, K ^a   Daley Yates, P T ^a   Feenstra, K L ^a   Koike, S ^a   Ozawa, N ^a   Peng, G W ^a   Sams, J P ^a   Schuette, M R ^a   Yamazaki, S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PNU 142300; PNU 142586; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; RAT; STEADY STATE; TOXICOKINETICS; URINARY EXCRETION;

ACETAMIDES; ANIMALS; ANTI-INFECTIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KINETICS; MALE; MASS SPECTROMETRY; MICE; MODELS, CHEMICAL; OXAZOLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TISSUE DISTRIBUTION;

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; POSIBACTERIA;

EID: 18644367890     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250210158249     Document Type: Article

References (26)

1. Boxenbaum, H., 1980, Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics, 8, 165-176.
2. Bratton, C. and Marshall, E. K., 1939, A new coupling agent for sulfanilamide determination. Journal of Biological Chemistry, 128, 537-539.
3. Chiba, K., Feenstra, K. L., Slatter, J. G., Daley-Yates, P., Duncan, J. N., Fagerness, P. E., Howard, M. R., Martin, I. J., Ozawa, N., Passingham, B. J., Parks, H. G., Peng, G. W., Simmonds, R. J., Speed, W., Yallop, D. and Yamazaki, S., 1998, Absorption, distribution, metabolism and excretion of the oxazolidinone antibiotic linezolid (PNU-100766) in the Sprague-Dawley rat. Poster at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, Poster A-123.
4. Demyan, W. F., Swaney, S. M. and Shinabarger, D. L., 1997, The oxazolidinone linezolid inhibits translation initiation in bacteria. In Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Abstract 5375.
5. Heinzel, G., Wolosczak, R. and Thomman, P., 1993, TOPFIT 2.0. Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC (Stuttgart: Gustav Fischer).
6. Heyrovsky, A., 1956, A new method for the determination of inulin in plasma and urine. Clinica Chimica Acta, 1, 470.
7. Jauch, R., Griesser, E., Oesterhelt, G., Arnold, W., Meister, W., Ziegler, W. H. and Guentert, T. W., 1990, Biotransformation of moclobemide in humans. Acta Psychiatrica Scandinavica Supplement, 360, 87-90.
8. Koike, S., Miura, H., Nakamura, R., Chiba, K. and Moe, J. B., 1995, Drug safety studies with a novel oxazolidinone U-100766. In Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, Abstract 5375.
9. Lin, A. H., Murray, R. W., Vidmar, T. J. and Marotti, K. R., 1997, The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with the binding of chloramphenicol and lincomycin. Antimicrobial Agents and Chemotherapy, 41, 2127-2131.
10. Nicholls, A. W., Lindon, J. C., Farrant, R. D., Shockcor, J. P., Wilson, I. D. and Nicholson, J. K. 1999, Directly-coupled HPLC-NMR spectroscopic studies of metabolism and futile deacetylation of phenacetin in the rat. Journal of Pharmaceutical and Biomedical Analysis, 20, 865-873.
11. Orloff, J. and Berliner, R. W., 1973, Handbook of Physiology, Section 8, Renal Physiology (Washington, DC: American Physiological Society), p. 229.
12. Pawsey, S. D., Daley-Yates, P. T., Wajszczuk, C. P. and Stalker, D. J., 1996, U-100766 Safety, toleration and pharmacokinetics after oral and intravenous administration. In Proceedings of the European Congress of Antimicrobial Chemotherapy, Abstract F151.
13. Peng, G. W., Stryd, R. P., Murata, S., Igarashi, M., Chiba, K., Aoyama, H., Aoyama, M., Zenki, T. and Ozawa, N., 1999, Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 20, 65-73.
14. Pharmacia Corp., 2000, Zyvox package insert. In Physicians' Desk Reference (Montvale: Medical Economics) [http://www.pdrel.com].
15. Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H. and Melchior, E. P., 1997, Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrobial Agents and Chemotherapy, 41, 2132-2136.
16. Sisson, T. A., Jungbluth, G. L. and Hopkins, N. K., 1999, Effect of age and gender on linezolid pharmacokinetics. In Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, Abstract 32.
17. 14C] linezolid to healthy human subjects. Drug Metabolism and Disposition, 29, 1136-1145.
18. Stalker, D. J., Wajszczuk, C. P. and Batts, D. H., 1997a, Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days. In Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
19. Stalker, D. J., Wajszczuk, C. P. and Batts, D. H., 1997b, Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days. In Proceedings of the 37th Interscience Conference on Antimicrobe Agents and Chemotherapy, Toronto, Canada.
20. Sun, J. X. S., Embil, K., Chow, D. S. L. and Lee, C. C. S., 1987, High-performance liquid chromatographic analysis, plasma protein binding and red blood cell partitioning of phenprobamate. Biopharmaceutics and Drug Disposition, 8, 341-351.
21. Swaney, S. M. and Shinabarger, D. L, 1997, Oxazolidinone mechanism of action: eperezolid inhibits the initiation event of protein synthesis in bacteria. In Proceedings of the 97th General Meeting of the American Society for Microbiology, Miami Beach, FL, USA, Abstract A-57.
22. Tanni, E, Rekka, E. and Kourounakis, P. N., 1994, Synthesis and effect on free radical processes of some substituted morpholine derivatives with potential biological activity. Arzeimittel Forschung/Drug Research, 44, 992-994.
23. Tocco, D. J., Duncan, A. E., deluna, F. A., Smith, J. L., Walker, R. W. and Vandenheuvel, W. J., 1980, Timolol metabolism in man and laboratory animals. Drug Metabolism and Disposition, 8, 236-240.
24. Vickers, S. and Polsky, S. L., 2000, The biotransformation of nitrogen containing xenobiotics to lactams. Current Drug Metabolism, 1, 357-389.
25. Wienkers, L. C., Wynalda, M. A., Feenstra, K. L., Gao, P. and Slatter, J. G., 1999, In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586. In Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA.
26. Wynalda, M. A., Hauer, M. J. and Wienkers, L. C., 2000, Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metabolism and Disposition, 28, 1014-1017.